Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

News provided by

Jan 03, 2024, 09:25 ET

GAITHERSBURG, Md., Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42^th Annual J.P. Morgan Healthcare Conference.

Conference Details:
Presentation and Q&A
Date:		Monday, January 8, 2024
Time:		5:15 – 5:55 p.m. Pacific Standard Time (PST)
Location:		Westin St. Francis Hotel in San Francisco, California
Moderator:		Eric Joseph, Ph.D., Executive Director, Biotechnology Equity Research
Novavax participants:		John C. Jacobs, President and Chief Executive Officer

Conference
Event:		Investor Meetings
Date:		Monday, January 8, 2024

Recordings
A replay of the recorded presentation and Q&A will be available through the Events & presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.

Contacts:
Investors
Erika Schultz
240-268-2022
[email protected]

Media
Ali Chartan
240-720-7804
[email protected]

SOURCE NOVAVAX, INC